Trials / Completed
CompletedNCT00997061
SCOT Registry: Small Cell Lung Cancer Treatment and Outcome
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 500 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The registry is an international, multicenter, observational registry of newly diagnosed patients with SCLC. Data will be entered into an electronic CRF (eCRF) via Internet access. Treatment plan remains the responsibility of the patient's physician and data collected in this registry will reflect a "real world" approach of the diagnosis and treatment of patients with SCLC. Approximately 60 centres in 13 countries will take part in this registry. It is expected that about 500 patients will be recruited during a period of 6 to 9 months according to the feasibility.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HYCAMTIN | Observing patients on HYCAMTIN and other drugs for SCLC. |
Timeline
- Start date
- 2009-11-01
- Primary completion
- 2012-02-01
- Completion
- 2012-02-01
- First posted
- 2009-10-16
- Last updated
- 2014-02-03
Locations
61 sites across 14 countries: Austria, Czechia, Estonia, France, Germany, Greece, Hungary, Italy, Lithuania, Netherlands, Poland, Slovenia, South Korea, Spain
Source: ClinicalTrials.gov record NCT00997061. Inclusion in this directory is not an endorsement.